Stakeholders hoping to see increased uptake of biosimilars in the United States are increasingly pointing to a lack of provider awareness as a key hindrance to the biosimilars marketplace. New research, to be presented at the American College of Rheumatology Annual Meeting in Chicago, Illinois, held from October 19-24, 2018, suggests that, despite efforts to educate providers, awareness of biosimilars—as well as awareness of patients’ attitudes toward them—remains low.
Stakeholders hoping to see increased uptake of biosimilars in the United States are increasingly pointing to a lack of provider awareness as a key hindrance to the biosimilars marketplace. New research, to be presented at the American College of Rheumatology Annual Meeting in Chicago, Illinois, held from October 19-24, 2018, suggests that, despite efforts to educate providers, awareness of biosimilars—as well as awareness of patients’ attitudes toward them—remains low.
First, a research team from Clinical Care Options and the University of Alabama sought to measure providers’ competence with biosimilars and address educational gaps related to these products using a 2-phase online program.1
The effort included a questionnaire that measured 1546 physicians’ knowledge of biosimilars before and after educational exercises. To address key gaps in awareness, the investigators developed their educational plan around questions that had a high frequency of incorrect responses at baseline.
At baseline, 61% of respondents—comprised of rheumatologists, gastroenterologists, dermatologists, allergists, immunologist, primary care physicians, oncologists, and other specialists—incorrectly reported that biosimilars have different efficacy from their reference products. Furthermore, 62% were not aware that biosimilars cannot be automatically substituted at the pharmacy level. Finally, 77% did not understand the concept of the extrapolation of indications for biosimilars.
After the educational program concluded, the absolute improvement in correct responses to questions from baseline was 37%, 33%, and 48% for the questions related to efficacy, substitution, and extrapolation, respectively.
The investigators concluded that these gaps in knowledge may explain why some clinicians are reluctant to consider biosimilars as treatment options for their patients.
A second research team, from Vindico Medical Education, found similar gaps in physician knowledge in their own study, based on a survey of 598 providers (rheumatologists, internists, and pharmacists) and 17 patients with rheumatoid arthritis.2
The investigators found that 49% of the providers felt their knowledge about differences between biosimilars and their reference products was “fair or poor.” Similarly, 66% lacked knowlege of the regulatory pathway for biosimilars.
Despite these gaps in understanding, 78% of rheumatologists reported that they would be comfortable prescribing a biosimilar, and 57% of pharmacists felt that biosimilars deemed interchangeable by the FDA should be substitutable at the pharmacy level (though only 16% of rheumatologists agreed with automatic substitution).
Notably, they also found that providers lacked awareness of what concerned their patients most about biosimilars. “Regarding patient concerns about biosimilars, physicians and pharmacists overestimated concerns regarding decreased efficacy and underestimated concerns regarding side effects,” wrote the authors. Patients’ greatest concern was being forced to switch products due to a payer decision, they found.
The researchers concluded that providers lack knowledge of biosimilars, and do not adequately understand patient’s concerns about these drugs. Continued educational efforts, they say, will be necessary to ensure the proper use of biosimilars.
References
1. Schwartz Z, Schulz J, Vinther A, Kuklinski A, Saag K. Uncovering clinicians’ gaps and attitudes toward biosimilars: impact of a 2-phase educational program. Presented at the American College of Rheumatology 2018 meeting, October 19-24, 2018; Chicago, Illinois. Abstract 2530. https://acrabstracts.org/abstract/uncovering-clinicians-gaps-and-attitudes-toward-biosimilars-impact-of-a-2-phase-educational-program/.
2. Robinson K, Esgro R. Revealing and addressing knowledge gaps regarding biosimilars in rheumatology practice with targeted continuing education and patient surveys. Presented at the American College of Rheumatology 2018 meeting, October 19-24, 2018; Chicago, Illinois. Abstract 2526. https://acrabstracts.org/abstract/revealing-and-addressing-knowledge-gaps-regarding-biosimilars-in-rheumatology-practice-with-targeted-continuing-education-and-patient-surveys/.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Patient-Reported Outcomes Similar Between Adalimumab-adbm, Reference Product in VOLTAIRE-RA Study
September 28th 2024A summary of research written by Vibeke Strand, MD, clinical professor in division of immunology/rheumatology at Stanford University School of Medicine, gave an overview of patient-reported outcomes (PROs) in the VOLTAIRE-RA trial.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).